Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I, Li LY, Jiao J, Hellemans P, Rasschaert F, de Zwart L, Snoeys J, De Meulder M, Mamidi RNVS, Ouellet D. Poggesi I, et al. Among authors: de zwart l, de meulder m. Eur J Drug Metab Pharmacokinet. 2020 Feb;45(1):101-111. doi: 10.1007/s13318-019-00581-9. Eur J Drug Metab Pharmacokinet. 2020. PMID: 31673875 Clinical Trial.
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
de Vries R, Smit JW, Hellemans P, Jiao J, Murphy J, Skee D, Snoeys J, Sukbuntherng J, Vliegen M, de Zwart L, Mannaert E, de Jong J. de Vries R, et al. Among authors: de zwart l, de jong j. Br J Clin Pharmacol. 2016 Feb;81(2):235-45. doi: 10.1111/bcp.12787. Epub 2016 Jan 15. Br J Clin Pharmacol. 2016. PMID: 26382728 Free PMC article. Clinical Trial.
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L, Snoeys J, Jacobs F, Li LY, Poggesi I, Verboven P, Goris I, Scheers E, Wynant I, Monshouwer M, Mamidi RNVS. De Zwart L, et al. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1107-1118. doi: 10.1002/psp4.12682. Epub 2021 Aug 11. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34273250 Free PMC article.
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
de Jong J, Hellemans P, De Wilde S, Patricia D, Masterson T, Manikhas G, Myasnikov A, Osmanov D, Córdoba R, Panizo C, de Zwart L, Snoeys J, Chauhan V, Jiao J, Sukbuntherng J, Ouellet D. de Jong J, et al. Among authors: de wilde s, de zwart l. Leuk Lymphoma. 2018 Dec;59(12):2888-2895. doi: 10.1080/10428194.2018.1460474. Epub 2018 May 30. Leuk Lymphoma. 2018. PMID: 29846137 Clinical Trial.
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emami Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N. Hariparsad N, et al. Among authors: de zwart l. Clin Pharmacol Ther. 2022 Oct;112(4):770-781. doi: 10.1002/cpt.2503. Epub 2021 Dec 24. Clin Pharmacol Ther. 2022. PMID: 34862964
40 results